



Patients in Need

MEDICINE SHORTAGES

iethico

www.iethico.com



February 2024



The Release of Generics in HRT Treatments



Amid a climate of changing demands and potential disruptions in the provision of treatments, pharmaceutical innovation stands as both a bulwark and beacon of hope. In a recent development, Besins Healthcare has shed light on this vital role by launching a new factory for the production of hormone replacement therapy (HRT) drugs.

As a critical aspect of women's health, the announcement is set to foster increased stability and access to a therapy that has been, at times, in short supply.



The Weight Loss Dilemma: Struggling to Keep Pace with Demand

In an era where health takes center stage and the pursuit of wellness becomes a persistent mantra, the narrative of effective weight management is more than a trending topic – it is a multibillion-dollar industry. At the axis of this narrative stand the hard facts: obesity remains a public health crisis, and the search for efficacious weight loss solutions has given rise to an insatiable demand for weight loss drugs. This surge in demand, notably for medications like Novo Nordisk's Wegovy and Eli Lilly's Saxenda, has left manufacturers racing to keep up, leaving patients and practitioners on the waitlist.

Novo Nordisk and Eli Lilly, pharmaceutical giants at the forefront of crafting solutions for weight management, have been witness to skyrocketing popularity for their respective drugs, semaglutide (Wegovy) and liraglutide (Saxenda). These medications, when combined with a reduced-calorie diet and increased physical activity, have demonstrated significant weight loss in clinical trials. However, their success story comes with a twist – they've become too successful for their own good.



Addressing the Shortage of ADHD Medications



ADHD is a chronic neurodevelopmental disorder that affects both children and adults, characterized by symptoms of inattention, hyperactivity, and impulsivity. For many, the cornerstone of managing these symptoms is through a judicious regimen of medication. The benefits of these medications are profound, often leading to improved concentration, enhanced cognitive function, and a significant reduction in impulsive behavior. In a broader context, these drugs play a pivotal role in patient quality of life, academic success, and professional fulfillment. Therefore, safeguarding the availability of ADHD medications is tantamount to preserving the overall well-being of the ADHD population.

Pharmaceutical shortages have become a disturbingly common global healthcare issue, posing formidable challenges for medical treatment, patient management, and health systems' operation. The current ADHD medication shortfall stands as an exemplar of this disturbing trend, affecting patients' access to vital medications.

The magnitude of the shortage is not to be underestimated: a significant portion of the population relies on these medications to manage their symptoms effectively. Professionals and patients alike are experiencing the ripple effects of this shortfall, which transcend beyond mere inconvenience to directly influence the quality of care and health outcomes.



Britain's Drug Shortages: Where is the Failure?



As Britain's health sector braces for potential drug shortages, a growing number of health professionals, policymakers, and industry experts are pointing fingers at the Medicines and Healthcare products Regulatory Agency (MHRA), arguing that its inefficiencies are a root cause of the looming crisis. What does this mean for the average Brit and those around the world who depend on the UK's pharmaceutical industry? This in-depth look at the interconnected web of drug shortages, regulatory oversights, and potential solutions aims to inform, raise awareness, and instigate change.

Causes of Drug Shortages in the UK

Understanding the multitude of causes behind the medication scarcity crisis is paramount to crafting effective solutions.

Choke Points in the System

The system's inefficiencies start with the regulatory process but do not end there. From manufacturers to pharmacies, any kink in the chain can disrupt the flow of vital medications.

Proactive Priorities

While emergencies may be unforeseeable, the preparedness of a regulatory body is not. A lack of proactive measures has led to a backlog of medications awaiting approval for sale, exacerbating supply chain fragilities.



Rabipur in shortage - available through iethico

RABIPUR works by stimulating your body's natural defense against rabies. It triggers the production of antibodies that fight and eliminate the rabies virus, protecting you from its harmful effects.

If you're in the UK and currently facing a shortage of RABIPUR, don't worry! iethico can help you access this vital vaccine. Sign up with us today to ensure your protection.

>> Rabipur vaccine powder and solvent for solution for injection 1ml pre-filled syringes

In simpler terms, Rabipur is a vaccine that guards against rabies.



iethico



Salbutamol in shortage - available through iethico

Salbutamol is used to relieve symptoms of asthma and chronic obstructive pulmonary disease (COPD) such as coughing, wheezing and feeling breathless. It works by relaxing the muscles of the airways into the lungs, which makes it easier to breathe. Salbutamol comes in an inhaler (puffer).

These are in shortage in the UK and iethico has a source available. You can sign up to get a quote for stock which is selling at or below DT price.

Salbutamol 2.5mg/2.5ml nebuliser liquid unit dose vials

Salbutamol 5mg/2.5ml nebuliser liquid unit dose vials



iethico

**MONITORING
YOUR PRODUCTS
FOR MEDICINE
SHORTAGES,**



**MEANS YOU'LL
KNOW SOONER
WHEN SOURCES
ARE AVAILABLE.**

Tap into the technology for
MEDICINE SOURCING

M A D E S I M P L E

Book a demo

Visit our contact page
<https://iethico.com/contact>